Results 111 to 120 of about 2,748,395 (254)

New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists

Biomedicines
Guidelines for the management of obesity and type 2 diabetes (T2DM) emphasize the importance of lifestyle changes, including a reduced-calorie diet and increased physical activity. However, for many people, these changes can be difficult to maintain over
Ferenc Sztanek, László Imre Tóth, Attila Pető, Marcell Hernyák, Ágnes Diószegi, Mariann Harangi   +5 more
doaj   +1 more source

The effects of portacaval shunt upon hepatic cholesterol synthesis and cyclic AMP in dogs and baboons [PDF]

, 1980
Hepatic cholesterol synthesis, hepatic cyclic AMP, and portal and peripheral insulin and glucagon levels were investigated in nine dogs and three baboons after complete portacaval shunt.
Benichou, J, Francavilla, A, Jones, AF, Starzl, TE   +3 more
core  

Deletion of Gpr27 in vivo reduces insulin mRNA but does not result in diabetes. [PDF]

, 2020
Gpr27 is a highly conserved, orphan G protein coupled receptor (GPCR) previously implicated in pancreatic beta cell insulin transcription and glucose-stimulated insulin secretion in vitro. Here, we characterize a whole-body mouse knockout of Gpr27. Gpr27
Chopra, Deeksha G, Hennings, Thomas G, Ku, Gregory M, Yiv, Nicholas, Zhang, Yaohuan   +4 more
core  

Portacaval shunt for glycogen storage disease and hyperlipidaemia. [PDF]

, 1977
Complete portacaval shunt was used to treat 10 patients with glycogen storage disease. A favourable effect was noted on body growth and a number of metabolic abnormalities.
Benichou, J, Porter, KA, Putnam, CW, Starzl, TE   +3 more
core  

Pancreatic polypeptide regulates glucagon release through PPYR1 receptors expressed in mouse and human alpha-cells.

Biochimica et Biophysica Acta, 2015
F. Aragón, M. Karaca, A. Novials, R. Maldonado, P. Maechler, B. Rubı́   +5 more
semanticscholar   +1 more source

Glucagon-like peptide-1 receptors in the brain: controlling food intake and body weight.

Journal of Clinical Investigation, 2014
L. Baggio, D. Drucker
semanticscholar   +1 more source

Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1

Proceedings of the National Academy of Sciences of the United States of America, 2007
H. Jang, Z. Kokrashvili, M. Theodorakis, O. Carlson, Byung-Joon Kim, Jie Zhou, Hyeon Ho Kim, Xiangru Xu, Sic L. Chan, M. Juhaszova, M. Bernier, B. Mosinger, R. Margolskee, J. Egan   +13 more
semanticscholar   +1 more source

GDF8 and activin A blockade protects against GLP-1–induced muscle loss while enhancing fat loss in obese male mice and non-human primates

Nature Communications
Glucagon-like peptide-1 receptor agonists act via appetite suppression and caloric restriction. These treatments can result in significant muscle loss, likely due to evolutionary mechanisms protecting against food scarcity as muscle is a major energy ...
Jason W. Mastaitis, Daniel Gomez, José G. Raya, Diana Li, Soo Min, Michael Stec, Sandra Kleiner, Toya McWilliams, Judith Y. Altarejos, Andrew J. Murphy, George D. Yancopoulos, Mark W. Sleeman   +11 more
doaj   +1 more source

Glucagon Receptor [PDF]

, 2020
openaire   +1 more source

A DPP-IV-resistant triple-acting agonist of GIP, GLP-1 and glucagon receptors with potent glucose-lowering and insulinotropic actions in high-fat-fed mice

Diabetologia, 2013
Vikas K. Bhat, B. D. Kerr, Srividya Vasu, P. Flatt, V. Gault   +4 more
semanticscholar   +1 more source